Revisiting CryoPort, Long-Term Opportunity & Risk (CYRX)

CryoPort, Inc. (CYRX) has been long-forgotten by many investors.  The question is whether or not it should be forgotten or whether it should be revisited.  This company provides cold chain frozen shipping systems primarily to the biotechnology, pharmaceutical, and life science sectors.  It was also recently given a bump up from a 60-Minutes feature earlier in January.  Shares popped up but they have listed back down and now they look lower than the price from the “news bump” in the stock from before that 60-Minutes feature brought attention to it.

This is one of those situations that is full of potential reward, but it is also full of potential risks.  It could rise massively, it could fold.  It could also raise capital in a dilutive manner. CryoPort is about as far away from a suitable situation for “widows and orphans strategies” as one could get.

This was featured as being the “highest medical standard” for safely and securely transporting cryogenically frozen materials.  Its solution transported stem cells to Duke University for testing and the combination of dry shipper technology and data monitoring allowed the Duke University team and 60 MINUTES to prove stem cell specimen viability.

The real issue is that the market cap remains tiny at under $21 million with shares round $0.75 and with a 52-week range of $0.65 to $1.73.  Volume is so small that it barely is worth the effort taken to publish these few paragraphs.

That being said, take a look at this one but you better do some deep research on your own before you make any decisions.  Again, not a move at all for widows and orphans nor for any funds which are not entirely set aside for pure risk-based capital.